John Lo

John Lo is a distinguished professional recognized for his leadership in commercializing and strategizing for the largest hematology portfolio globally. With a track record of successfully launching 5 New Molecular Entities (NMEs) spanning small molecules, biologics, and cell therapy, he has made substantial contributions to the pharmaceutical industry.

John Lo's academic background includes a Doctor of Philosophy (PhD) in Biochemistry and Molecular Biology from the prestigious Massachusetts Institute of Technology (MIT), reflecting his strong foundation in the life sciences.

Throughout his career, John Lo has held key executive positions in renowned pharmaceutical companies, demonstrating his expertise in the field. He has served as the Senior Vice President of WW Hematology at Bristol-Myers Squibb and Corporate Vice President of Global Marketing for Hematology & Oncology at Celgene. Additionally, he has contributed significantly in roles such as Head of Global Marketing and Market Access at AstraZeneca, VP Global Immuno-oncology and Lung Cancer Franchises, and VP Global Lung Cancer Franchise Head at AstraZeneca. His diverse experience includes Executive Business Director of the Hematology Franchise at Novartis, VP US Hematology Franchise Head on an interim basis at Novartis, US Exjade Brand Lead, US Tasigna Marketing, and Sales roles at Novartis. He has also served as the Executive Director of Strategic Planning at Novartis and as an Associate Principal at McKinsey & Company, showcasing his comprehensive understanding of the pharmaceutical landscape.

John Lo's achievements in steering commercial strategies and global initiatives, particularly in the hematology sector, underscore his ability to drive innovation and navigate complex market landscapes effectively. His wealth of experience spanning various leadership roles equips him with a holistic perspective in shaping successful business strategies.